Radiodermatitis can be classified
as acute or chronic. The acute condition occurs within 90 days of exposure to
radiation, whereas the chronic condition may occur from 15 days to 10 years or
more after the beginning of radiation therapy. Topical products, oral
medications, and dressings are used in the treatment and management of
radiodermatitis.
The global Radiodermatitis
Market is estimated to account for US$ 360.5 Mn in terms of value and is
expected to reach US$ 472.8 Mn by the end of 2027.
Global Radiodermatitis Market:
Drivers
High risk of chronic
radiodermatitis after fluoroscopically guided interventions is expected to
propel growth of the global radiodermatitis market over the forecast period.
For instance, according to the study, ‘Incidence of Chronic Radiodermatitis
after Fluoroscopically Guided Interventions: A Retrospective Study’, published
in the Journal of Vascular and Interventional Radiology in May 2019, 8.8% of
the patients adopting fluoroscopically guided interventions suffered from
chronic radiodermatitis.
Global Radiodermatitis Market:
Opportunities
Lack of definitive/standard
treatment creates ambitious avenue for a breakthrough, thereby offering
lucrative growth opportunities for players in the global radiodermatitis
market. Radiation dermatitis symptoms
are typically managed with a variety of topical agents such as water-based
moisturizing creams or lotions, topical steroids, anti-inflammatory emulsions,
and wound dressings. However, even with these options, there is no standard
treatment currently for the prevention of radiation-induced dermatitis with
proven effectiveness. This leads to a tremendous opportunity for the
introduction of a breakthrough treatment, which can be considered as standard
care and effective in the amelioration of radiation-induced skin damage.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3881
Global Radiodermatitis Market:
Restraints
Stringent regulatory scenario is
expected to hinder growth of the market. Treatment products for radiation
dermatitis are required to undergo clinical trials and approval by regulatory
bodies. Conducting trials and filing for approval for novel innovations is a
time-consuming process and also requires substantial financial investment. The
termination or inefficacy to get a standard treatment through certain studies
pertaining to this market could create a deterrent for new players, which could
restrain growth of the market.
Key Takeaways:
The global radiodermatitis market
was valued at US$ 346.9 Mn in 2019 and is forecast to reach a value of US$
472.8 Mn by 2027 at a CAGR of 3.9% between 2020 and 2027. Major factor driving
the growth of global radiodermatitis market during the forecast period
increasing prevalence of cancer, and product launches and approvals for
Radiodermatitis treatment.
Topical agents held dominant
position in the global radiodermatitis market in 2019, accounting for 70.5%
share in terms of value, followed by dressing and oral medication,
respectively. Ease of application of topical agents is expected to support
growth of the segment.
Retail pharmacies segment held dominant position in the
global radiodermatitis market in 2019, accounting for 38.9% share in terms of
value.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/radiodermatitis-market-3881
Market Trends
In New Zealand, Swedish
silicon-foam skin dressing, Mepilex Lite (Mölnlycke Health Care, Sweden) is used
for the treatment of burns and slow healing wounds. Silver-leaf nylon dressing
has proven to have effective antimicrobial activity and enhances healing in
burns and skin grafts. Non-adherent dressings such as silicone dressing and no
sting barrier film dressings are also recommended for the treatment of
radiodermatitis.
E-commerce is a major
distribution channel in the market. For instance, 3M offers Cavilon no sting
barrier film for online sale on its official website as well as retail websites
such as Amazon. RadX, Stratpharma, Molnlycke Health Care, Medline Industries,
and Advancis Medical are key players in this market that have their major
products available online.
Global Radiodermatitis Market:
Competitive Landscape
Major players operating in the
global radiodermatitis market include, Acelity, Inc. (3M), BMG Pharma S.r.l.,
ConvaTec Group PLC, DermaSciences Inc. (Integra LifeSciences Holdings
Corporation), Intermed Pharmaceuticals, Molnlycke Health Care, Smith & Nephew
Plc, Stratpharma AG, Kannalife, Inc., and Jay Pharma
Global Radiodermatitis Market:
Key Developments
September 2019: ConvaTec Group
Plc signed an agreement to purchase the assets of Southlake Medical Supplies,
Inc., a U.S.-based independent provider of catheter-related supplies
July 2019: Integra LifeSciences
Holdings Corporation acquired Arkis Biosciences Inc., a privately-held company
that offers a portfolio of neurosurgical devices
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3881
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment